PLAUR and urinary bladder carcinoma: Accordingly, a plethora of uPAR-targeting PET-probes mostly based on the high-affinity 9-mer antagonist peptide AE105 have been synthesized and tested preclinically in diverse human xenograft mouse models and, recently, also in two clinical uPAR PET studies in humans, including prostate, breast, and bladder cancer patients, with promising results [17,22,23,24,25,28,160].